【结 构 式】 |
【分子编号】69273 【品名】(1S,4S,5S)-tert-butyl 3-oxo-2-oxabicyclo[2.2.1]heptane-5-carboxylate 【CA登记号】 |
【 分 子 式 】C11H16O4 【 分 子 量 】212.24564 【元素组成】C 62.25% H 7.6% O 30.15% |
合成路线1
该中间体在本合成路线中的序号:(XII)Lactone acid (VI) is amidated with N-methylhex-5-enamine (VII) in the presence of O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HATU) and DIEA in DMF at 0 °C. The resulting lactone amide (VIII) is opened with LiOH in THF/methanol/H2O and the intermediate carboxylic acid is then condensed with the hydrochloride of amine (IX) by means of DIAD and HATU in DMF, producing hydroxyamide (X) . Finally, alcohol (X) and quinolinol derivative (XI) are coupled under Mitsunobu conditions (PPh3, DIAD) in THF .
Alternatively, lactone acid (VI) is esterified with di-tert-butyl dicarbonate (Boc2O) in the presence of DMAP in CH2Cl2, providing the tert-butyl-protected lactone (XII), which is then opened by treatment with LiOH in dioxane/H2O at 0 °C. Amidation of the in situ-generated acid with the vinylcyclopropyl amino acid ester (IX) (in its hydrochloride form) in DMF at 0 °C gives amino acid (XIII), which is coupled with the quinoline moiety (XI) by a Mitsunobu reaction (PPh3, DIAD) in THF at 0 °C, affording adduct (XIV), with the proper configuration of the chiral center at position 3 of the cyclopentane. Subsequent deprotection of the tert-butyl ester (XIV) with triethylsilane and TFA in CH2Cl2 followed by condensation of the resulting acid with alkenylamine (VII) by means of DIAD and HATU in DMF at 0 °C yields the desired noncyclic diene (I) .
【1】 Raboisson, P., De Kock, H., Rosenquist, A. et al. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett 2008, 18(17): 4853-8. |
【2】 Stokbroekx, S.C.M., Leys, C., Swinney, K.A., Wuyts, S., Horvath, A. (Tibotec Pharmaceuticals Ltd.). Polymorphic forms of a macrocyclic inhibitor of HCV. WO 2008092954. |
【3】 Raboisson, P.J.-M.B., De Kock, H.A., Hu, L. et al. (Tibotec Pharmaceuticals Ltd.; Medivir AB). Macrocyclic inhibitors of hepatitis C virus. CA 2616580, EP 1912999, JP 2009502889, WO 2007014926. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 69263 | (1S,2R)-ethyl 1-((1S,2S,4S)-2-(hex-5-en-1-yl(methyl)carbamoyl)-4-((2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-yl)oxy)cyclopentanecarboxamido)-2-vinylcyclopropanecarboxylate | C39H50N4O6S | 详情 | 详情 | |
(VI) | 69267 | (1S,4S,5S)-3-oxo-2-oxabicyclo[2.2.1]heptane-5-carboxylic acid | C7H8O4 | 详情 | 详情 | |
(VII) | 69268 | N-methylhex-5-enamine;N-methylhex-5-en-1-amine | C7H15N | 详情 | 详情 | |
(VIII) | 69269 | (1R,4S)-N-(hex-5-en-1-yl)-N-methyl-3-oxo-2-oxabicyclo[2.2.1]heptane-5-carboxamide | C14H21NO3 | 详情 | 详情 | |
(IX) | 69270 | (1R,2S)-ethyl 1-amino-2-vinylcyclopropanecarboxylate | 746657-36-3 | C8H13NO2 | 详情 | 详情 |
(X) | 69271 | (1R,2S)-ethyl 1-((1S,2S,4R)-2-(hex-5-en-1-yl(methyl)carbamoyl)-4-hydroxycyclopentanecarboxamido)-2-vinylcyclopropanecarboxylate | C22H34N2O5 | 详情 | 详情 | |
(XI) | 69272 | 7-methoxy-8-methyl-2-[4-(1-methylethyl)-2-thiazolyl]-2-4-Quinolinol;(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-ol | 923289-21-8 | C17H18N2O2S | 详情 | 详情 |
(XII) | 69273 | (1S,4S,5S)-tert-butyl 3-oxo-2-oxabicyclo[2.2.1]heptane-5-carboxylate | C11H16O4 | 详情 | 详情 | |
(XIII) | 69274 | (1S,2S,4S)-tert-butyl 2-(((1S,2S)-1-(ethoxycarbonyl)-2-vinylcyclopropyl)carbamoyl)-4-hydroxycyclopentanecarboxylate | C19H29NO6 | 详情 | 详情 | |
(XIV) | 69275 | (1S,2S,4S)-tert-butyl 2-(((1S,2S)-1-(ethoxycarbonyl)-2-vinylcyclopropyl)carbamoyl)-4-((2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-yl)oxy)cyclopentanecarboxylate | C36H45N3O7S | 详情 | 详情 |